ArchiveMarch 2012

NICE & CCSVI

NICE interventional procedure guidance 420. Percutaneous venoplasty for chronic cerebrospinal venous insufficiency for multiple sclerosis Issued: March 2012. Current evidence on the efficacy of percutaneous venoplasty for chronic cerebrospinal venous insufficiency (CCSVI) for multiple sclerosis (MS) is inadequate in quality and quantity. Therefore, this procedure should only be used in...

China stops unapproved stem cell treatments

Don Durfee & Sally Huang. China stops unapproved stem cell treatments. Reuters, BEIJING | Tue Jan 10, 2012 5:52am EST. “China has ordered a halt to all unapproved stem cell treatments and clinical trials, state media reported on Tuesday, as Beijing seeks to rein in the largely untested stem cell therapies now on offer across the country. The Ministry of Health will stop accepting new...

MS Life – Saturday 14th April

After my recent experience talking to MSers at the Redbridge branch of the MS Society I need to rethink my presentation at MS Life. The following is a draft programme for the Saturday: Saturday 14 April (Day 1)    11:00 – 11:30 MS Society welcome 11:30 – 12:15 Rehabilitation – Prof. Alan Thompson 12:15 – 13:00 Myelin Repair – Prof. Charles ffrench...

Meta-analysis of randomised controlled MS trials

Epub ahead of print:  Zintzaras et al.  Network Analysis of Randomized Controlled Trials in Multiple Sclerosis. Clin Ther. 2012 Mar 21.  BACKGROUND: The optimal treatment of MS is not yet well-defined. OBJECTIVE: To estimate the relative effectiveness of treatments in MS, we performed a network of multiple-treatments meta-analysis of randomized controlled trials...

March:Unrelated blogger comments 2

Sometimes you what to say something that is unrelated to the threads.
This is a spot for You. (This post may move around abit)
If you do not see you comment appear, it has been spammed by Google. There is an offensive word, term in there, reword and it should repost

Research: Remyelination and Galanin.. another way

Zhang et al. Galanin Transgenic Mice with Elevated Circulating Galanin Levels Alleviate Demyelination in a Cuprizone-Induced MS Mouse Model.PLoS One. 2012;7(3):e33901. Epub 2012 Mar 19. MS is a demyelinating autoimmune disease of the central nervous system (CNS) with a presumed autoimmune etiology. Approved treatments for MS are immunoregulatory and are able to reduce the inflammatory components...

Fatigue and the energetic costs of walking

Epub ahead of print:  Kempen et al.  Self-Reported Fatigue and Energy Cost During Walking Are Not Related in Patients With Multiple Sclerosis.Arch Phys Med Rehabil. 2012 Mar 20.  OBJECTIVES:  To determine whether there is a relationship between self-reported fatigue and the energy cost of walking (ECw), and how self-reported fatigue and ECw relate to physical functioning...

Alemtuzumab 5 year follow up

Coles AJ, et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial.Neurology. 2012 Mar 21. [Epub ahead of print] OBJECTIVE: To report the long-term safety and efficacy results from CAMMS223 comparing alemtuzumab with interferon β-1a in early, active relapsing-remitting multiple sclerosis (RRMS). What are the long-term effects of alemtuzumab treatment...

Research: Use it or Lose It

Epub: Sumowski JF et al. Cognitive reserve in secondary progressive multiple sclerosis. Mult Scler 2012. Background: Consistent with the cognitive reserve hypothesis, lifetime intellectual enrichment protects MS patients from cognitive impairment. As studies have focused predominately on patients with relapsing-remitting courses, it is unknown whether lifetime enrichment is protective against...

Translate

Categories

Recent Posts

Recent Comments

Archives